Home / Health / Novartis Scraps Heart Drug Amidst Study Failure

Novartis Scraps Heart Drug Amidst Study Failure

7 Nov

Summary

Novartis is discontinuing pelacarsen's development.
The drug showed little promise in preventing heart attacks.
Analysts previously viewed the drug as a potential blockbuster.

Novartis AG has decided to discontinue the development of pelacarsen, an experimental drug once anticipated to be a blockbuster. This decision comes after a recent study indicated that the drug offered minimal promise in preventing heart attacks and cardiovascular deaths.

The pharmaceutical giant will halt all further development of pelacarsen, which was being investigated for conditions related to atherosclerotic cardiovascular disease. This move signifies a considerable departure from the initial high expectations held by analysts for the drug's potential market success.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.